{"id":1635,"date":"2024-10-26T06:57:29","date_gmt":"2024-10-26T04:57:29","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/"},"modified":"2024-10-26T06:57:30","modified_gmt":"2024-10-26T04:57:30","slug":"comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/","title":{"rendered":"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2022\/kidney.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/hires\/2022\/kidney.jpg\" data-sub-html=\"Credit: Pixabay\/CC0 Public Domain\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>La n\u00e9phropathie \u00e0 IgA (IgAN) est une maladie r\u00e9nale auto-immune provoqu\u00e9e par des cellules immunitaires qui expriment \u00e0 leur surface une prot\u00e9ine appel\u00e9e CD38. Un r\u00e9cent essai de phase II a r\u00e9v\u00e9l\u00e9 que le felzartamab, un anticorps monoclonal anti-CD38 exp\u00e9rimental, aide \u00e0 r\u00e9duire la prot\u00e9inurie et \u00e0 maintenir la fonction r\u00e9nale des patients.<\/p>\n<p>Les enqu\u00eateurs ont \u00e9valu\u00e9 les m\u00e9canismes mol\u00e9culaires qui sous-tendent l&rsquo;efficacit\u00e9 potentielle du felzartamab dans les IgAN. Les r\u00e9sultats ont \u00e9t\u00e9 pr\u00e9sent\u00e9s lors de l\u2019ASN Kidney Week 2024, du 23 au 27 octobre.<\/p>\n<p>On suppose que CD38<sup>+<\/sup> les cellules contribuent \u00e0 la maladie par la s\u00e9cr\u00e9tion d\u2019IgA1 d\u00e9ficientes en galactose (Gd-IgA1) ainsi que d\u2019anticorps anti-Gd-IgA1, qui forment ensuite des complexes immuns qui se d\u00e9posent dans les reins et provoquent une inflammation et une perte de fonction r\u00e9nale en aval.<\/p>\n<p>Dans leur analyse, les chercheurs ont examin\u00e9 le sang total et le s\u00e9rum pr\u00e9lev\u00e9s sur des patients atteints d&rsquo;IgAN avant, pendant et apr\u00e8s le traitement par felzartamab. Les \u00e9chantillons ont \u00e9t\u00e9 \u00e9valu\u00e9s pour les cellules immunitaires, les anticorps et les immunoglobulines, notamment Gd-IgA1.<\/p>\n<p>Les analyses ont r\u00e9v\u00e9l\u00e9 que le felzartamab induisait une d\u00e9pl\u00e9tion rapide et durable des anticorps Gd-IgA1 et IgA totaux. Les patients qui ont re\u00e7u neuf doses sur une p\u00e9riode de traitement de six mois ont maintenu une r\u00e9duction des IgA1 en Gd jusqu&rsquo;\u00e0 neuf mois sans traitement.<\/p>\n<p>De plus, la r\u00e9duction totale des IgA a \u00e9t\u00e9 maintenue pendant au moins 18 mois sans traitement. En revanche, les titres totaux d&rsquo;anticorps IgG du corps ont \u00e9t\u00e9 l\u00e9g\u00e8rement r\u00e9duits et r\u00e9cup\u00e9r\u00e9s dans les quatre mois sans traitement, ce qui sugg\u00e8re la pr\u00e9servation des composants de la r\u00e9ponse immunitaire adaptative du corps.<\/p>\n<p>\u00ab\u00a0Ces donn\u00e9es approfondissent notre compr\u00e9hension du r\u00f4le du CD38<sup>+<\/sup> cellules s\u00e9cr\u00e9tant des anticorps dans la pathogen\u00e8se de la n\u00e9phropathie \u00e0 IgA \u00bb, a d\u00e9clar\u00e9 l&rsquo;auteur correspondant Millie Shah, Ph.D., scientifique principale chez Biogen.<\/p>\n<p>\u00ab\u00a0En \u00e9puisant directement ces cellules, le felzartamab r\u00e9duit les facteurs cellulaires responsables de la maladie et pr\u00e9sente le potentiel d&rsquo;un b\u00e9n\u00e9fice clinique durable sans administration continue, r\u00e9duisant potentiellement le fardeau du patient et offrant une meilleure tol\u00e9rance.\u00a0\u00bb<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La n\u00e9phropathie \u00e0 IgA (IgAN) est une maladie r\u00e9nale auto-immune provoqu\u00e9e par des cellules immunitaires<\/p>\n","protected":false},"author":1,"featured_media":476,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[1366,2005,182,2006,2008,2007,1760],"class_list":["post-1635","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-affecte","tag-anticorps","tag-comment","tag-felzartamab","tag-iga","tag-nephropathie","tag-nouvel","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"La n\u00e9phropathie \u00e0 IgA (IgAN) est une maladie r\u00e9nale auto-immune provoqu\u00e9e par des cellules immunitaires\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-26T04:57:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-26T04:57:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA\",\"datePublished\":\"2024-10-26T04:57:29+00:00\",\"dateModified\":\"2024-10-26T04:57:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/\"},\"wordCount\":410,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg\",\"keywords\":[\"affecte\",\"anticorps\",\"comment\",\"felzartamab\",\"IgA\",\"n\u00e9phropathie\",\"nouvel\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/\",\"name\":\"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg\",\"datePublished\":\"2024-10-26T04:57:29+00:00\",\"dateModified\":\"2024-10-26T04:57:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg\",\"width\":1920,\"height\":1600,\"caption\":\"Les bienfaits cardiovasculaires du s\u00e9maglutide sont maintenus chez les personnes souffrant d'insuffisance r\u00e9nale, selon une \u00e9tude\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/","og_locale":"fr_FR","og_type":"article","og_title":"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA - RVH-Synergie.org","og_description":"La n\u00e9phropathie \u00e0 IgA (IgAN) est une maladie r\u00e9nale auto-immune provoqu\u00e9e par des cellules immunitaires","og_url":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/","og_site_name":"RVH-Synergie","article_published_time":"2024-10-26T04:57:29+00:00","article_modified_time":"2024-10-26T04:57:30+00:00","og_image":[{"width":1920,"height":1600,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA","datePublished":"2024-10-26T04:57:29+00:00","dateModified":"2024-10-26T04:57:30+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/"},"wordCount":410,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg","keywords":["affecte","anticorps","comment","felzartamab","IgA","n\u00e9phropathie","nouvel"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/","url":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/","name":"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg","datePublished":"2024-10-26T04:57:29+00:00","dateModified":"2024-10-26T04:57:30+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1726448688_Les-bienfaits-cardiovasculaires-du-semaglutide-sont-maintenus-chez-les-personnes.jpg","width":1920,"height":1600,"caption":"Les bienfaits cardiovasculaires du s\u00e9maglutide sont maintenus chez les personnes souffrant d'insuffisance r\u00e9nale, selon une \u00e9tude"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/comment-le-nouvel-anticorps-felzartamab-affecte-la-nephropathie-a-iga\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"Comment le nouvel anticorps felzartamab affecte la n\u00e9phropathie \u00e0 IgA"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=1635"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1635\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/476"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=1635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=1635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=1635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}